Revelation Biosciences REVB 深 滬
已收盤 07-31 16:00:00 美东时间
0.95
-0.045
-4.56%
華盛通- 最 高1.01
- 今 開1.00
- 成交量 2.37万股
- 最 低 0.95
- 昨 收 0.9954
- 總市值 371.30万
- 52周最高 11.72
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 0.875
- 委 比 7.76%
- 總股本 390.84万
- 歷史最高 2276064.00
- 量 比 0.97
- 振 幅 6.03%
- 歷史最低 0.95
- 每 手 1
- 風險率 3.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Revelation Biosciences Adopts Stockholder Rights Protection Plan
An update from Revelation Biosciences ( ($REVB) ) is now available. On July 10,...
07-14 05:12
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that its Board of Directors (the "Board") has adopted a stockholder rights plan (the "Rights Plan") a...
07-11 04:07
Revelation Biosciences Updates Executive Contracts, Shareholder Actions
Revelation Biosciences ( ($REVB) ) has shared an update. On June 24, 2026, Reve...
06-25 05:19
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
05-09 00:05
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over losses of $(25.34) per
05-08 04:56
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30,
03-30 21:02
Revelation Biosciences Shareholders Approve Warrant Share Issuance
Revelation Biosciences ( ($REVB) ) has shared an announcement. On March 18, 202...
03-20 04:51
Revelation Biosciences reports FY results
Revelation Biosciences press release (REVB): FY net loss of $59.76. As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024...
02-27 20:02
